Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
2,4-diamino-6-[N-(2',5'-dimethoxybenzyl)-N-methylamino]quinazoline
- Development stage
- Preclinical
- Lead developer
- Duquesne University
- Modality
- Small Molecules
01
Overview
2,4-Diamino-6-[N-(2',5'-dimethoxybenzyl)-N-methylamino]quinazoline is an experimental small molecule belonging to the quinazolinamine class. It was designed as a lipophilic inhibitor of dihydrofolate reductase (DHFR), with potent activity against DHFR from various species including Toxoplasma gondii and Pneumocystis carinii. The compound has demonstrated nanomolar inhibitory potency in vitro and has also shown inhibition of tumor cell growth in culture. Its mechanism involves competitive inhibition at the DHFR active site, interfering with folate metabolism essential for DNA synthesis and cell proliferation[1][5][7]. No approved clinical indications or marketed formulations exist for this compound.
- Other names
- 2,4-diamino-6-[N-(2',5'-dimethoxybenzyl)-N-methylamino]quinazolineN6-(2,5-dimethoxybenzyl)-N6-methylquinazoline-2,4,6-triamine
02
Targets
DHFR (Dihydrofolate reductase)TgDHFR-TS (Toxoplasma gondii dihydrofolate reductase-thymidylate synthase)
Beyond the preview
Go deeper on 2,4-diamino-6-[N-(2',5'-dimethoxybenzyl)-N-methylamino]quinazoline.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 2,4-diamino-6-[N-(2',5'-dimethoxybenzyl)-N-methylamino]quinazoline.